JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma

• Nobukazu Fujimoto,
• Yosuke Miyamoto,
• Sae Wada,
• Katsuyuki Hotta,
• Toshiyuki Kozuki,
• Keisuke Aoe,
• Jun Sakurai,
• Michihiro Yoshida,
• Daijiro Harada

Affiliations

Nobukazu Fujimoto

Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan

Yosuke Miyamoto

Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan

Sae Wada

Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan

Katsuyuki Hotta

Center of Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan

Toshiyuki Kozuki

Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

Keisuke Aoe

Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan

Jun Sakurai

Center of Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan

Michihiro Yoshida

Center of Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan

Daijiro Harada

Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan